Noninterventional studies of depot formulations of LHRH analogues for prostate cancer in routine clinical practice. The launch of an observational program to assess the use of Eligard 45 mg in Russia
https://doi.org/10.17650/1726-9776-2015-1-68-72
Abstract
Open-label observational studies can objectively assess treatment in routine clinical practice, which is important from both the scientific and pharmacoeconomical points of view. In 2013, a multicenter open-label prospective observational EQUILIBRIUM study was initiated to describe the Russian experience with Eligard 45 mg used to treat disseminated prostate cancer (PC) in routine clinical practice. A total of 623 patients who had different stages of PC and had been previously treated for this condition were included in the program. The mean age of the patients was 68.9±8.55 years; their mean level of prostate-specific antigen was equal to 42.2 ng/ml and that of testosterone was 89 ng/dl. At the same time, pretreatment testosterone concentrations were measured in only one third of the patients. When included in the program, the patients had a rather high quality of life as evidenced by the EQ-5D-5L questionnaire: its mean index was 0.84±0.18 scores (complete well-being was taken as 1); the mean visual analogue scale health status scores were 75.15±16.5 mm (0, worst health; 100, best health). During the study, most patients received hormone therapy with Eligard 45 for locally advanced PC and distant metastases were detectable in only 15.89 % of the patients.
About the Authors
V. B. Matveev
N.N. Blokhin Russian Cancer Research Center; 23, Kashirskoe Shosse, Moscow 115 478, Russia
Russian Federation
Russian Federation
A. S. Markova
N.N. Blokhin Russian Cancer Research Center; 23, Kashirskoe Shosse, Moscow 115 478, Russia
Russian Federation
Russian Federation
References
1. Вольская Е.А. Основы надлежащей практики неинтервенционных исследований лекарственных препаратов. Качественная клиническая практика 2011;1:19–24. [Volskaya E.A. The essentials of good clinical practice for non-interventional drug studies. Kachestvennaya klinicheskaya praktika = Good clinical practice 2011;1:19–24. (In Russ.)].
2. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use.
3. Ouzaid I., Roupret M. The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: results from the ‘ELIRE’ observational study. Prog Urol 2011;21:866–74.
4. Montorsi F., Tomlinson P. Which luteinising hormone-releasing hormone agonist injection schedule do men with prostate cancer prefer? Results of a European patient survey. Eur Urol (2014). http://dx.doi.org/10.1016/j. eururo.2014.08.055Г
5. Perez-Marrero R., Chu F.M., Gleason D. et al. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24:1902–14.
6. Chu F.M., Jayson M., Dineen M.K. et al. A clinical study of 22.5 mg. LA-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168:1199–203.
7. Crawford E.D., Sartor O., Chu F. et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175:533–6.
8. Herdman M., Gudex C., Lloyd A. et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research 2011;20(10): 1727–36.
9. Tunn Ulf W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology 2011. http://www.biomedcentral. com/1471-2490/11/15
10. Braeckman J., Michielsen D. Efficacy and tolerability of 1and 3-month leuprorelin acetate depot formulations (Eligard®/DepoEligard®) for advanced prostate cancer in daily practice: a Belgian prospective noninterventional study. Arch Med Sci 2014;10(3):477–483.
Review
For citations:
Matveev V.B., Markova A.S. Noninterventional studies of depot formulations of LHRH analogues for prostate cancer in routine clinical practice. The launch of an observational program to assess the use of Eligard 45 mg in Russia. Cancer Urology. 2015;11(1):68-72. (In Russ.) https://doi.org/10.17650/1726-9776-2015-1-68-72
Views:
1420
Email this article 